An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - Sommerer, Claudia; Suwelack, Barbara; Dragun, Duska; Schenker, Peter (Kidney international, 2019)
Published online 27 February 2019